A study suggests GLP-1 medicines, which are widely used for diabetes and weight management, could eventually be tailored more closely to individual patients. If confirmed, this could help clinicians choose treatments and doses that better match a person’s likely response and side-effect risk.

The article text provided does not include the study’s methods, findings, sample size or publication details because access to the page was denied. As a result, the reported potential for personalised treatment cannot be assessed further from the available material.